Although current biomarker research primarily focuses on tumor PD-L1, microsatellite instability (MSI), and tumor mutational burden (TMB) (Lin et al. 2023), significant heterogeneity and controversies make clinical application challenging. Here, CD274 is linked to neoplasm.